A proven track record
Brookhaven is a pioneer in positron emission tomography and its uses in drug developement with a proven record of working with pharmaceutical and biotechnology companies.
Brookhaven National Laboratory (BNL) on Long Island, New York, has a proven track record of using Positron Emission Tomography (PET) to improve drug discovery and development. BNL is a pioneer and leader in this field, advancing medical imaging technology for over 50 years. BNL's PET Imaging Group has a long history of widely cited investigations of the neurochemical circuits that are disrupted in diseases of addiction and in pathological eating disorders (obesity) as well as working with pharmaceutical and biotech organizations under collaborative arrangements to study various aspects of drug development.
If you are developing a new drug or studying new uses of an old drug and need information on mechanisms, sites of action, dosing amounts, dosing schedules, and/or possible side effects, BNL's PET Imaging Group can help you get the results you need.
BNL has all the resources needed for utilizing PET and MRI imaging in drug development, from producing radioisotopes, to designing and synthesizing radiolabeled drugs and tracers, to writing and implementing protocols to running animal and human studies.
BNL's professional staff includes specialists in chemistry, radiotracer design and testing, animal studies, physics, engineering, imaging design and testing, pharmacology, neuropsychology, neuroscience, clinical studies, neurology, psychiatry, kinetic modeling, nursing, protocol development, data management and other fields involved in PET imaging and drug development.
For more information, or to arrange a visit, contact:
BNL Office of Technology Commercialization & Partnerships
See a list of all available radiotracers. (Other radiotracers described in the literature can also be transferred to our lab.)